

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Purchase of Own Shares

Further to the confirmation of its intention to implement a share buyback programme, as set out in its announcement on 29 March 2022, the Company announces that it has purchased a total of 1,625,000 of its ordinary shares at a price of 42.4985 pence per share. The ordinary shares purchased will be held in treasury.

Aggregated information

Date of purchase	5 April 2022
Number of ordinary shares purchased	1,625,000
Highest price paid per share	42.6
Lowest price paid per share	42
Volume weighted average price paid	42.4985

Transaction details

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018), a detailed breakdown of individual trades is available below:

Number of ordinary shares purchased	Transaction price (GBP)	Time of transaction	Trading venue
100,000	42	16:35:45	AIMX
125,000	42	16:16:08	AIMX
50,000	42	15:59:03	AIMX
1,000,000	42.6	09:19:26	AIMX
350,000	42.6	09:06:19	AIMX

Total voting rights

Following the purchase, the Company's total issued share capital will consist of 463,930,564 ordinary shares of 1 pence each ("Ordinary Shares") each carrying one voting right, of which 7,575,000 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 456,355,564. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

EKF Diagnostics Holdings plc
Mike Salter, CEO
Marc Davies, CFO

www.ekfdiagnostics.com
via Walbrook PR

Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell / George Tzimas / Tom Salvesen

+44 (0)20 7496 3000

Investec Bank plc (Joint Broker)
Gary Clarence / Daniel Adams

+44 (0)20 7597 4000

Walbrook PR Limited
Paul McManus / Lianne Applegarth

+44 (0)20 7933 8780 or
ekf@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

Point-of-Care	Providing a portfolio Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.
Central Laboratory	Clinical chemistry, Small lab analysers, Centrifuges <i>Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycates Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin</i>
Life Sciences	Enzyme fermentation, Custom products and Bulk fermentation
Contract Manufacturing	Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits
Laboratory Services	In September 2021, EKF completed the acquisition of Advanced Diagnostic Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. The laboratory provides testing for a variety of clinical, forensic and microbiological sample types using a range of analytical techniques. This acquisition positions EKF as a leading 'one stop' provider of diagnostic products and services from sample collection to results.

In May 2021, EKF announced its strategy for delivering growth to 2024 and beyond, and continuing to deliver shareholder value. The strategy for growth can be summarised as:

- continuing innovation in products and services in Point-of-Care, Central Laboratory and Life Sciences leveraging new and existing routes to market and relationships;
- investment in expanded production and kitting capabilities to offer a suite of diagnostic Contract Manufacturing solutions to third party businesses;
- expansion of CLIA Laboratories Testing offering building on the acquired capabilities in ADL Health; and
- identify complementary earnings-enhancing acquisitions with key strategic value.

EKF will also continue to generate enhanced shareholder value through:

- a progressive dividend policy; and
- its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us advanced access to innovative commercial opportunities and where we can build on the ongoing successes of Renalytix plc, Verici Dx plc and Trelus Health plc.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSBKPBKABKDNQK admin Purchase of Own Shares 32586212 A Wed, 04/06/2022 - 07:00 LSE
RNS Transactions in Own Shares EKF